Asston Pharmaceuticals is coming with its IPO, which is one of the fastest-growing pharmaceutical firms that specializes in selling medical products across the world. The new 22.41 lakh shares being issued by Asston Pharmaceuticals IPO are priced between ₹115 and ₹123 per share, with a face value of ₹10 per share. The opening date of the IPO is going to be 7th July 2025, while the closing date on 9th July 2025. The IPO offering size is 1000 shares in one lot and for a retail individual investor, a minimum investment of 2000 shares is needed.

Company Background

Asston Pharmaceuticals Limited was founded in 2019 with the goal of distributing a variety of medical supplies throughout the world. Its offerings include tablets, capsules, sachets and syrups across various therapeutic areas like antibiotics, antifungals and vitamins. The company operates through both direct sales and contract manufacturing or a loan license agreement under a principal-to-principal model. Because of the company's Central and State FDA certifications, NQA accreditation, and adherence to QMS standards, high-quality production is guaranteed.

Operations and Product Range

Facility and Production

Asston Pharmaceuticals IPO has manufacturing facilities with a capacity to produce 8–9 crore tablets per month, 30–40 lakh sachets monthly and approximately 37,500 liters of syrups each month. The company’s production adheres to high-quality standards as it is certified by the Central and State FDA, accredited by NQA and compliant with Quality Management System (QMS) protocols. This ensures consistent manufacturing of pharmaceutical products including tablets, capsules, syrups and sachets.

Brand and Market Presence

The company has its brand name “Asston” under which it markets its products and also manufactures products with contract manufacturing or license agreements for other marketers as well. The product line of the company includes important therapeutic categories such as vitamins, antibiotics, antifungals and more. Asston Pharmaceuticals IPO has created a significant position in both domestic and international markets by exporting its products in the Asian and African nations.

Revenue Channels

Asston Pharmaceuticals IPO generates revenue primarily through:

• Contract Manufacturing (Loan License / B2B): For major revenue, the company mainly produces pharmaceutical products for third-party marketers under loan license agreements.
• Branded Product Sales: Another major chunk of revenue comes from selling formulation drugs under the company's brand name “Asston”, including tablets, syrups and sachets.
• Export Sales: Asston also exports its pharmaceutical and nutraceutical products to the African and Asian region, which also help in the company’s revenue.
• OTC & Nutraceutical Products: Offering over-the-counter formulations such as vitamin syrups and mineral supplements through retail and pharmacy channels.

Management & Shareholding

Promoters & Shareholding
Asston Pharmaceuticals IPO is promoted by Dr. Ashish Narayan Sakalkar, Saili Jayaram More, and Sachin Chandrakant Badakh. Before the IPO, promoters held 68.76% equity, which will reduce to 50.66% post-issue.

Board Members
The board includes Managing Director Dr. Ashish Sakalkar and Director/CEO Saili More, both appointed in April 2019. In June 2024, Sachin Badakh became a Non-Executive Director. Independent directors Rishabh Kumar Jain and Vijaya Shahapurkar also serve on the board.